Cooper Companies, Inc. (The) (NYSE:COO) updated its FY17 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $9.66-9.76 for the period, compared to the Thomson Reuters consensus estimate of $9.63. The company issued revenue guidance of $2.13-2.14 billion, compared to the consensus revenue estimate of $2.13 billion.Cooper Companies, Inc. (The) also updated its Q4 guidance to $2.60-2.70 EPS.
Several analysts have recently commented on the stock. Piper Jaffray Companies raised their price objective on shares of Cooper Companies, Inc. (The) to $265.00 and gave the company an overweight rating in a research report on Wednesday, July 19th. BidaskClub downgraded shares of Cooper Companies, Inc. (The) from a strong-buy rating to a buy rating in a report on Tuesday, July 25th. Jefferies Group LLC reiterated a buy rating and issued a $250.00 price target on shares of Cooper Companies, Inc. (The) in a report on Tuesday. Stephens reiterated an equal weight rating and issued a $250.00 price target (up from $235.00) on shares of Cooper Companies, Inc. (The) in a report on Tuesday. Finally, Zacks Investment Research downgraded shares of Cooper Companies, Inc. (The) from a buy rating to a hold rating in a report on Thursday, June 22nd. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $257.60.
Shares of Cooper Companies, Inc. (COO) opened at 247.00 on Friday. Cooper Companies, Inc. has a 12-month low of $158.73 and a 12-month high of $256.39. The stock has a 50 day moving average of $245.27 and a 200-day moving average of $224.26. The company has a market capitalization of $12.07 billion, a P/E ratio of 37.03 and a beta of 0.59.
Cooper Companies, Inc. (The) (NYSE:COO) last issued its earnings results on Thursday, August 31st. The medical device company reported $2.64 EPS for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.06. The business had revenue of $556.00 million during the quarter, compared to analysts’ expectations of $552.32 million. Cooper Companies, Inc. (The) had a net margin of 16.45% and a return on equity of 16.00%. The company’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.30 earnings per share. Equities research analysts forecast that Cooper Companies, Inc. will post $9.72 EPS for the current year.
In related news, Director Gary S. Petersmeyer sold 3,977 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $244.94, for a total transaction of $974,126.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $244.23, for a total transaction of $1,465,380.00. Following the sale, the chief operating officer now owns 34,395 shares of the company’s stock, valued at $8,400,290.85. The disclosure for this sale can be found here. Insiders sold 20,992 shares of company stock valued at $5,167,628 over the last quarter. Company insiders own 1.60% of the company’s stock.
Cooper Companies, Inc. (The) Company Profile
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with our FREE daily email newsletter.